General discussion, page-1850

Good find G.

Yeah I think we got a different supplier for dronabinol. Probably because IHL changed their plans for the drug.

Any old holders will remember like Jan 2019 where the 4 trials news and partnership with Cannvalate came out. The initial trial was really just dronabinol for OSA intended to be able to sell under the SAS in Australia. That is likely why we partnered with RespireRX.

The plan changed to pursue FDA registration in major markets, and the trial changed from a simple one that was likely just a Phase 1B/2A to a 2B trial. The trial protocol had to be completely re-written to be in accordance with FDA regulations and that's why it's taken so long compared to the old guidance. The entire trial is different now, far more robust and intended for a completely different outcome than it was initially.

And we are all the better off for it.